We are revolutionizing intracellular therapeutic development through a non-viral, non-toxic platform for safe and targeted molecular delivery. Our mission is to offer safe and affordable treatment solutions for a wide range of diseases from cancer to cystic fibrosis and to improve the quality of life of our patients. Our goal is to become leaders in the next generation therapeutics. We are committed to improving the quality of life of patients worldwide. We are innovation-driven and patient-inspired to realize a new vision for the delivery of better health outcomes. INDIA CYGENICA PRIVATE LIMITED 700 NIP, NCL Innovation Park, Dr. IRELAND CYGENICA PRIVATE LIMITED C/O O' Connor Pyne & Co. We focus on solving the huge challenge surrounding targeted intracellular delivery of cancer drugs and other biological therapies.
Pune, India
Founded in 2017
1-10 Employees
Working industry
Research
Type of company
Manufacturer
Ownership structure
Privately Held
Locations
2 Locations
Number of products
1 Product
Specialised areas
Biotechnology
CyGenica offers a wide range of products and services
Product
CyGenica
Go to product >
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
India
Overall risk estimation:
High
The ESG Data of countries are based on public sources
Environment
E
Grade (A-E)
View details
Social
D
Grade (A-E)
View details
Governance
C
Grade (A-E)
View details
CyGenica operates in 1 country around the world
Get an overview of the locations of CyGenica
Location
Country
State
City
Headquarter
India
Maharashtra
Pune
India Office
India
Maharashtra
Pune
Some frequent questions that have been asked about CyGenica
Where is CyGenica located?
The company headquarter of CyGenica is located in Pune, Maharashtra, India. CyGenica has subsidiaries in India
How many employees does CyGenica approximately have?
As of the latest available information CyGenica has around 1-10 employees worldwide.
When was CyGenica founded?
CyGenica was founded in 2017
In which industries does CyGenica mainly work?
The company CyGenica has it's main focus in the industries of Research
Check out some interesting alternative companies to CyGenica
Nanocell Therapeutics
Utrecht, Netherlands
1-10 Employees
-
Our goal is to revolutionize current cell and gene therapy practices by eliminating the need for ex-vivo cell manipulations. At NanoCell we develop in vivo gene therapies harnessing our non-viral, DNA-based, cell directed, technology platform. Our goal is to transform the cell and gene therapy field by converting adoptive cell therapies into gene therapies. Ultimately, we are committed to ensuring patients have access to exceptional therapeutic options worldwide. While many in the field focus on viral or RNA-based methods, we uniquely harness the lasting potential of DNA, delivered through our advanced non-viral vector technology. At NanoCell, we unite top talent and experts deeply anchored in science, spanning from multidisciplinary research to drug development, as well as corporate and business leadership. Geerlings is an experienced executive and serial entrepreneur who has co-founded and led multiple successful biotech companies . Hrubiec is a distinguished intellectual property attorney, as well as a Ph.D.
CureGenetics
Suzhou City, China
51-100 Employees
2016
Cure Genetics, is a clinical-stage biotechnology dedicated to developing first-in-class cell and gene therapies for solid tumors and genetic disorders through our innovative AIMS CAR-NKT and VELPTM AAV discovery platforms. We aim to provide effective treatment measures for patients worldwide with unmet medical needs and to become a benchmark in the global field of cell and gene therapies. Founded Cure Genetics in 2016, dedicated to developing innovative gene and cell therapies for genetic diseases and tumors. Ren is a seasoned expert in cell therapy, boasting over 20 years of experience developing and advancing cell therapy drug candidates from pre-clinical to commercial licensure across US, EU, and Japan. Ren has supported multiple IND submissions for cell therapy pipeline products to enable clinical trials and designed and led process & analytical validation programs in support of commercial registration filing. Shawn will guide the navigation of Cure Genetics' cell therapy development, leading the team to break new ground and accelerate the progress of cell therapy pipelines. We have built 4000m2 R&D, enzyme raw material manufacturing and IVD GMP manufacturing center in order to quickly promote the registration filings of our core products.
SE-Therapeutics
Évry, France
1-10 Employees
2022
We develop new methods of delivering biologics into cells to drive the next generation of cell and gene therapies. The increasingly aging population of the industrial world is leading to an increase in the number of patients suffering from neurological diseases and cancers. However, cell therapy manufacturers are confronted with complex workflows and scalability issues. Production is currently only economically feasible at a small scale.
Dynamk Capital
New York, United States
1-10 Employees
2017
CellFE Biotech is enabling the next generation of cell and gene therapies by efficiently delivering gene-editing payloads with high throughput, and preserving cell function and viability. Envisagenics' mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence. Superior technologies and solutions for the production of recombinant proteins in E. Vernal Biosciences provides mRNA and LNP-mRNA manufacturing services to democratize the use of mRNA for all use cases ranging from drug discovery to clinical development across all use cases such as gene editing and regulation, cellular programming, vaccines, mRNA replacement, oncology, autoimmune, and protein degradation. Virica Biotech’s Viral Sensitizer (VSE™) platform reduces production inefficiencies caused by innate anti-viral defenses in manufacturing cells. Customizable solutions substantially increase manufacturing yields and reduce the cost of goods for a range of products, including vaccines, cell and gene therapies, and anti-cancer therapies. Xcell Bioscience’s mission is to enhance the performance and safety of cell and gene-based therapies through the design and development of revolutionary technology platforms. We will keep you up to date on Dynamk Capital news and content.
Cyanagen Srl
Bologna, Italy
11-50 Employees
2003
Cyanagen Srl is an Italian biotech company founded in Bologna in 2003. Cyanagen’s product lines are available for CUSTOM OEM sales according to clients’ specifications. Cyanagen offers its clients the manufacturing of starting materials in bulk and customized products ready for sales. Our products are based on Cyanagen internationally patented technologies and achieve outstanding performance in terms of sensitivity and stability. Cyanagen sells its product lines also in OEM and OEM CUSTOM. Our products or clients’ customised ones can be available in bulk, bottled or fully packed kits options. Cyanagen also offers a wide range of services in chemical research and organic synthesis in life science. We, at Cyanagen, shall aim to achieve and sustain excellence in all our activities.
Incisive Genetics
Vancouver, Canada
1-10 Employees
2018
We believe the proprietary Incisive Delivery System™ provides a solution to the most critical challenge to effective CRISPR-based gene therapy — the effective and safe delivery of active gene editing machinery into in vivo target tissues. There is a unique opportunity in the gene therapy space for development of a “true” platform delivery technology. Incisive Genetics’ OmniaTM platform is a proprietary, non-viral delivery method for CRISPR-based gene therapies. There is a unique opportunity in the gene therapy space for development of a superior platform delivery technology. The Incisive Delivery System™ is a proprietary, non viral delivery method for CRISPR based gene therapies. Kevin Chow has over two decades of experience leading business development and corporate strategy in both large and small biopharmaceutical companies. Pamela Wagner is the Director of R&D Operations at Incisive Genetics Inc. Hayden is a Killam Professor at the University of British Columbia, the highest honour UBC can confer on any faculty member.